Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Carfilzomib Therapy in Previously Treated Patients
NCT00884312Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2009
- Primary completion
- May 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib in multiple myeloma (MM) and solid tumor, sponsored by Amgen. Primary endpoints: Number of Participants With Peripheral Neuropathy and Number of Participants With Adverse Events. Started Apr 2009; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)solid tumor
Beyond the preview
Go deeper on NCT00884312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884312.